Go back to trials list
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Description
This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.This is a single arm, open label, clinical trial to evaluate the feasibility and safety of oral tazemetostat followed by standard of care CAR T cell infusion in previously treated DLBCL, FL, and MCL. The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill l
Trial Eligibility
Inclusion Criteria: * Confirmed diagnosis of DLBCL, FL, or MCL * Eligible to receive standard of care CAR T cells * Have received at least 1 prior therapies Exclusion Criteria: * Active viral infection with HIV or hepatitis type B or C * Active, uncontrolled systemic fungal, bacterial or viral infection * Active treatment for another cancer * Pregnant or breastfeeding * Unable to take oral medication * Certain significant past medical history, such recent stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias
Study Info
Organization
Weill Medical College of Cornell University
Primary Outcome
Number of participants who experience adverse events classified per CTCAEv5
Interventions
Locations Recruiting
Weill Cornell Medicine/NewYork-Presbyterian Hospital
United States, New York, New York
Interested in joining this trial?
Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.
Get the latest thought leadership on your Mantle Cell Lymphoma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.